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Abstract 
Spurious increase in erythrocyte mean corpuscular volume 
(MCV) on automated cell analyzers is a well-characterized lab 
error in hypertonic patients.  A difference between automated and 
manual MCV (dMCV) greater than 2fl has been shown to predict 
hypertonicity in humans.  The purpose of this study was to 
investigate dMCV as a marker for serum hypertonicity in dogs and 
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to examine the relationship between dMCV and three methods of 
estimating serum tonicity: measured (OsMM), calculated (OsMC), 
and calculated effective (OsMCE) osmolalities.  OsMC, OsMCE, and 
dMCV were calculated from routine blood values and OsMM was 
directly measured in 121 dogs.  The dMCV of hypertonic dogs was 
significantly larger than that of normotonic dogs for all three 
osmolality methods.  dMCV predicted hypertonicity as estimated 
by OsMM better than it predicted hypertonicity as estimated by 
OsMC and OsMCE.  A cut-off of 2.96fl yielded the best sensitivity 
(76%) and specificity (71%) for hypertonicity estimated by OsMM. 
 





Serum hypertonicity is an important clinical problem in 
both human and veterinary medicine.  Hypertonicity, also known 
as effective hyperosmolality, is defined as an elevated serum 
concentration of solutes that draw fluid out of cells by osmosis (i.e. 
effective osmoles or osmoles with tonic effect) (Wellman et al. 
2012).  At a tissue level, hypertonicity can lead to cellular 
dysfunction by altered function of the protein macromolecular 
apparatus, decreased protein synthesis, changes in cell membrane 
function, and breaks in nucleic acid strands (Garner and Berg 
1994; Lang et al. 1998; Alfieri and Petronini 2007).  At a systemic 
level, hypertonicity is associated with a variety of clinical 
conditions and has been investigated as an early indicator for 
progression of several disease states (Stookey et al. 2007a; Stookey 
2005; Clegg et al. 2013; Stookey et al. 2004a; Stookey et al. 
2004b; Schemerhorn and Barr 2006; Kotas et al. 2008). 
In the Third National Health and Nutrition Examination 
Survey (NHANES III), a cross-sectional survey of non-
hospitalized individuals, the prevalence of hypertonicity (OsM  ≥ 
300 mOsM) in human adults in the U.S. is estimated at 20% with 
borderline hypertonicity (OsM = 295-300 mOsM) affecting an 
additional 40% of the population (Stookey 2005).  Higher 
prevalence has been associated with age, obesity, race, and diabetic 
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status (Stookey et al. 2007a; Stookey 2005).  Hypertonicity may 
also be an early indicator for frailty, a condition of decreased 
functional reserve of the body and vulnerability to systemic 
morbidity, especially common in the elderly (Stookey et al. 2004b, 
Clegg et al. 2013).  A longitudinal study of older adults found that 
plasma hypertonicity was an independent predictor for the onset of 
disability within a four-year period and mortality within an eight-
year period (Stookey et al. 2004b).  Hypertonicity is particularly 
important clinical problem for insulin-resistant and diabetic 
patients.  In NHANES III, the prevalence of hypertonicity in 
human diabetics (identified by fasting glucose or oral glucose 
tolerance test or by self-reporting by the subject) was reported as 
35-78% (Stookey 2005).  In human hyperglycemic, pre-diabetic 
patients, hypertonicity has been shown to be a risk factor for 
progression to diabetes mellitus, with hypernatremia having an 
independent effect on disease progression (Stookey et al. 2004a).  
In diabetic dogs and cats, the prevalence of effective 
hyperosmolality was reported as 81% (Schemerhorn and Barr 
2006).  Interestingly, in diabetic animals, sodium (Na) 
concentrations appear to be highly associated with osmolality 
(tonicity), emphasizing the importance of this solute in diabetic 
patients (Schemerhorn and Barr 2006, Kotas et al. 2008). 
 5 
Clinically, tonicity can be difficult to quantify because this 
value not only includes solute concentrations but encompasses the 
physiologic effects of multiple solutes on the cell.  Tonicity can be 
approximated by osmolality (OsM), the number of total solutes or 
osmoles per kilogram solvent. In biologic (i.e. aqueous) solutions, 
osmolality is equivalent to osmolarity (osmoles/L solvent), which 
can be measured directly (measured osmolality, OsMM) or 
calculated using commonly measured laboratory values (calculated 
osmolality OsMC, Eq. 1).  However, OsMM is a quantification of 
all osmoles in solution, both effective and ineffective, without 
regard to tonic effect and thus may overestimate tonicity.  An 
alternative approach is to calculate the calculated effective 
osmolality, OsMCE, (Eq. 2) from commonly measured solutes 
known to be effective osmoles (sodium [Na], potassium [K], 
glucose).  However, OsMCE may underestimate tonicity because 
some serum osmoles that are not measured or included in the 
calculation may have a tonic effect.  Calculated total osmolality 
(OsMC) may fall prey to both these limitations because ineffective 
osmoles are included in its calculation (i.e. blood urea nitrogen 
[BUN]) and because some effective unmeasured osmoles may not 
be included in the calculated estimate (Wellman et al. 2012).  
Because it is impractical to measure every solute with known or 
possible tonic effect, true tonicity is almost impossible to 
 6 
rigorously quantify.  However, because tonicity exerts a 
physiologic effect (changes in cell size), a physiologic 
measurement of tonicity would be preferable to absolute 
quantification. 
Spurious increase in red blood cell (RBC) mean 
corpuscular volume (MCV) is a well-characterized lab error that 
occurs when blood from hypertonic patients is assessed by an 
automated cell analyzer.  In vivo, RBCs are acclimated to the 
hypertonic patient serum.  In vitro, when RBCs from hypertonic 
patients are placed into the isotonic analyzer media, they swell 
because the analyzer solution is relatively hypotonic to the 
intracellular environment causing an intracellular fluid shift 
(Stockham and Scott 2008a).  Stookey et al. (2007a) exploited this 
“lab error” to develop a new index for plasma hypertonicity.  The 
MCV difference (dMCV) is the difference between the MCV as 
measured by an automated cell analyzer (MCVM) and the MCV 
calculated from a spun hematocrit (hct), which is performed with 
RBCs in the original patient plasma (Eq. 3).  A cutoff value of only 
2 fl or greater for dMCV performed well as an indicator for 
hypertonicity and, when combined with elevated plasma 
vasopressin levels, yielded 100% sensitivity and specificity 
(Stookey et al. 2007b). 
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Use of dMCV to detect hypertonicity has not been 
investigated in veterinary patients.  The purpose of the present 
study was to investigate dMCV as a marker for serum 
hypertonicity in dogs and to examine the relationship between 
dMCV and three methods of estimating serum tonicity: OsMM, 
OsMC, and OsMCE.  It was hypothesized that dMCV would be a 
useful marker for hypertonicity and that an elevated dMCV would 
predict hypertonicity estimated by OsMCE better than it would 
predict hypertonicity estimated by OsMM or OsMC. 
 
Materials and Methods 
Cases – Patient records at the Kansas State University 
Veterinary Health Center were searched to identify all animals 
admitted to the small animal intensive care unit (SA-ICU) between 
February 1, 2012 and May 16, 2012.  Records were identified 
using a SA-ICU charge as a search criterion for the hospital 
practice management software.
a
  In addition, certain SA-ICU 
admissions from November 1, 2011 to January 31, 2012 had been 
identified for inclusion; on several days during this time period, the 
medical record numbers of all dogs present in the SA-ICU were 
recorded by hand and subsequently screened for study inclusion.  
Cases were included if the patient was a dog, if a complete blood 
                                                          
a Vetstar, Advanced Technology Corp.; Oak Ridge, TN 
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count (CBC) and a biochemistry profile were performed during the 
hospital visit, and if stored serum from the biochemistry profile 
was available for further analysis.  Dogs were excluded if anemia 
was present.  For the purposes of this study, anemia was defined as 
a low RBC concentration ([RBC] < 5.5 M/μl) on the CBC.  This 
study was performed in accordance with the Kansas State 
University guidelines for animal research. 
Clinical Pathology – All CBCs (ethylenediaminetetraacetic acid 
anticoagulated blood) and serum biochemistry profiles were 
performed by the Kansas State Veterinary Diagnostic Lab Clinical 
Pathology Laboratory within 24 hours of collection. All laboratory 
tests were performed by certified medical technologists.  CBCs 
were performed using the Advia 2120 Hematology System;
b
 spun 
hct using a microcentrifuge and card hct reader was included as a 
standard part of the CBC.  Biochemistry profiles were performed 
using the COBAS C501 Chemistry Analyzer.
c
  Serum samples 
were then frozen at –20°C until identified for use in the study at 
which point they were transferred to a -80°C freezer where they 
were stored until batch osmometry measurements could be made.  
                                                          
b Siemens Medical Solutions, Inc.; Malvern, PA.  OsM of the RBC 
diluent is 280 mOsM 
c Roche Diagnostics; Indianapolis, IN 
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Serum OsMM was measured in duplicate by freezing-point 
depression using the Micro-OSMETTE osmometer.
d
 
Calculations – The following values measured as part of 
the CBC were included in calculation of dMCV: measured mean 
corpuscular volume (MCVM), spun hct, and RBC.  The following 
values measured as part of the serum biochemistry profile were 
included in serum osmolality calculations: Na concentration, K 
concentration, glucose concentration, and BUN concentration.  
OsMC (Eq. 1) and OsMCE (Eq. 2) were determined using standard 
clinical formulas (Wellman et al. 2012). 
Eq. 1       (    )   
   
   
  
       
  
 
Eq. 2        (    )   
       
  
 
The dMCV (Eq. 3) was calculated by as previously reported 
(Stookey et al. 2007b). 
Eq. 3             
       
   
 
Data Analysis – Continuous data are represented as median 
and range.  dMCV data were assessed for normality using the 
Shapiro-Wilk test.  For each method of estimating tonicity (OsMM, 
OsMC, and OsMCE), dogs were categorized into a normosmolar 
group (OsM < 320 mOsM) and a hyperosmolar group (OsM ≥ 320 
mOsM).  Because only one dog would have been considered 
                                                          
d Precision Systems, Inc.; Natick, MA 
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hypoosmolar (OsM < 280mOsM) using measured osmolality 
(OsMM = 279mOsM) and no dogs were hypoosmolar using OsMC 
or OsMCE, a hypoosmolar group was not included in analysis; the 
aforementioned dog was included in the normosmolar group for 
OsMM analysis.  For each method of estimating tonicity, the 
dMCV of the normosmolar group and the dMCV of the 
hyperosmolar group were compared using a Student’s t-test.  The 
ability of dMCV to predict hypertonicity, as estimated by each 
osmolality method, was determined using a receiver operator curve 
(ROC) curve; cut-off values to maximize sensitivity and specificity 
were visually determined.  Area under the ROC curve (AUROC) 
was calculated for each osmolality method and these were 
compared. 
A post hoc analysis was performed to establish a dMCV 
cut-off for mild hypertonicity, defined as OsMM ≥ 300 mOsM.  
The dMCV of normosmolar (OsMM < 300 mOsM) and 
hyperosmolar (OsMM ≥ 300 mOsM) dogs were compared using a 
Student’s t-test; an ROC curve was generated and a cut-off value 
maximizing sensitivity and specificity was visually determined.  
All statistical analyses were performed using commercial 
software.
e
  A p-value less than 0.05 was considered statistically 
significant. 
                                                          




 Two hundred and eighty-nine cases were identified from 
the records search (n = 255) or previously recorded (n = 34).  One 
hundred and one cases were excluded because they were not dogs, 
did not have a CBC and biochemistry panel performed during 
hospitalization, or did not have stored serum available for further 
analysis.  An additional 67 dogs were excluded because they were 
found to be anemic.  One-hundred and twenty-one dogs were 
included in the final analysis.  The median age of all dogs was 7.08 
years (range 1 month to 16 years).  Fifty-eight dogs were neutered 
males and 44 were neutered females; 14 dogs were intact males 
and five were intact females.  Pertinent clinicopathologic values, 
measured osmolality, and calculated values are summarized in 
Table 1. 
 Regardless of the method used to estimate tonicity (OsMM, 
OsMC, OsMCE), the dMCV for hyperosmolar dogs was 
significantly larger than the dMCV for normosmolar dogs (Table 
2).  ROC curves for dMCV predicting OsMM, OsMC, and OsMCE 
are depicted in Figure 1.  A dMCV of 2.96 fl, 2.47 fl, and 2.96 fl 
provided maximal sensitivity and specificity for predicting 
hypertonicity as estimated by OsMM, OsMC, and OsMCE, 
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respectively.  dMCV best predicted hypertonicity as estimated by 
OsMM (AUROC = 0.7738, Table 3). 
 The finding that dMCV could predict hypertonicity defined 
as OsMM ≥ 320 mOsM prompted the question whether dMCV 
might predict smaller elevations in measured osmolality.  A post-
hoc analysis was performed using hypertonicity defined as OsMM 
≥ 300 mOsM.  The dMCV for hyperosmolar dogs (2.82 fl; -2.60 – 
6.92 fl) was significantly larger than that of normosmolar dogs 
(0.75 fl; -2.95 – 3.50 fl; p < 0.001).  An ROC analysis was 
performed (AUROC = 0.8021; Figure 2); a dMCV cut-off of 1.49 
fl yielded a 75% sensitivity and 76% specificity. 
 
Discussion 
 The results of this study support the hypothesis that dMCV 
can be used as a physiologic marker for hypertonicity in 
hospitalized canine patients.  This finding was anticipated because 
red blood cells acclimated in a hypertonic solution (i.e. patient 
plasma) swell when placed into isotonic solution (i.e. cell analyzer 
media).  Interestingly, dMCV predicted serum hypertonicity best 
when tonicity was estimated using measured osmolality (OsMM ≥ 
320 mOsM) rather than calculated effective osmolality (OsMCE).  
This differs from the original hypothesis: it was suspected that 
dMCV would be a better marker for OsMCE because, as a 
 13 
physiologic marker of tonicity, dMCV should only be susceptible 
to changes in effective osmole concentrations; it should not be 
affected by changes in ineffective osmole concentrations, such as 
BUN, which are included in OsMM and OsMC.  Indeed, dMCV did 
perform better for OsMCE (AUROC = 0.7337) than it did for OsMC 
(AUROC = 0.7063), which includes BUN as well as Na, K, and 
glucose.  Thus, it can be inferred that dMCV is not heavily 
influenced by BUN and this may hold true for some or all other 
ineffective osmoles.  However, dMCV predicted hypertonicity as 
estimated by OsMM better than by either calculated method.  The 
difference between measured and calculated osmolality is known 
as the osmolar gap and consists of all osmoles, effective and 
ineffective, not routinely measured.  Because unmeasured osmoles 
are included in OsMM and because dMCV performs best for 
predicting OsMM, it is likely that at least a portion of the 
unmeasured osmoles act as effective osmoles, influencing dMCV 
and therefore the physiologic effects of hypertonicity on RBCs. 
In this study, dogs were divided into normosmolar and 
hyperosmolar groups using 320 mOsM as a cut-off for OsMM, 
OsMC, and OsMCE.  This value was initially chosen in order to 
include only dogs with clinically relevant hypertonicity in the 
hyperosmolar group.  However, in certain situations, it may be 
useful to identify mild hypertonicity as is the case in humans in 
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whom it was shown that mild hypertonicity (OsMM ≥ 300 mOsM) 
was a risk factor for frailty in the elderly and for progression of 
disease in pre-diabetic patients (Stookey et al. 2004b; Stookey et 
al. 2004a).  Therefore, the canine data was reexamined to 
determine dMCV performance when mild hyperosmolality is 
present.   Using a lower cut-off for dMCV ( ≥ 1.5 fl) for mild 
hypertonicity (OsMM ≥ 300 mOsM) performed as well as the 
higher dMCV cut-off (≥ 3 fl) did for overt hypertonicity (OsMM ≥ 
320 mOsM).  This gradated cut-off system may be useful in future 
longitudinal studies investigating disease progression or markers 
for various morbidities. 
 It is important to recognize that RBC size is not solely 
governed by tonicity, so changes in erythrocyte volume in response 
to hyper- or hypotonicity are complex and may be different than 
anticipated.  Part of this phenomenon may be due to the biconcave 
shape of the mammalian erythrocyte.  Changes in cell volume alter 
the conformation of the erythrocyte cytoskeleton leading to a 
change in cell membrane cell curvature (Wong 2006).  Therefore, 
if cell volume is derived from measurements of cell diameter, 
volume may be underestimated.  In the present study, RBCs were 
subjected to ‘sphering’ treatment to produce homogenous spheres 
by the cell analyzer prior to analysis, so biconcave structural 
effects were eliminated.  The sphering technique is standard 
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practice for most RBC analyzers and has been shown to render 
accurate and repeatable measurements of RBC size (Kim and 
Ornstein 1983).  Plasma and intracellular proteins exert an effect 
on fluid balance through oncotic pressure, which varies according 
to size, structure, and charge of the protein moieties.  Because 
changes in net oncotic pressure can elicit fluid shifts independently 
of tonicity, plasma protein concentrations may alter cell size (in 
either direction) from values predicted based on plasma tonicity 
alone (Wellman et al. 2012).  Albumin is the most important 
plasma determinant of oncotic pressure, contributing 
approximately 80% of the total plasma colloid osmotic pressure 
(Wellman et al. 2012).  Finally, and most importantly, all 
mammalian cells have the ability to regulate volume through a 
variety of active processes, which allow the cell to acclimate 
during periods of osmotic stress as well as participate in a variety 
of metabolic functions (Lang et al. 1998; Alfieri and Petronini 
2007; Haussinger 1996; Schliess et al. 2007).  The cellular 
compensation for hypertonic-induced cell shrinkage is termed 
regulatory volume increase (RVI) and the response to hypotonic-
induced cell swelling, regulatory volume decrease (RVD) (Alfieri 
and Petronini 2007; Schliess et al. 2007).  Early responses to cell 
shrinkage or swelling include increased membrane ion transport 
followed by transport of small non-ionic organic molecules 
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(osmolytes) including alcohols, methylamines, and amino acids.  
These compensatory mechanisms precipitate a partial RVI or RVD 
within seconds to minutes of initial fluid shifts.  The late response 
to tonic change involves activation (or inhibition) of a variety of 
cellular pathways that lead to the production of heat shock proteins 
and to novel synthesis of intracellular osmolytes.  These processes 
require up- or down-regulation of gene expression, so complete 
volume compensation (RVI or RVD), if it occurs, takes hours to 
days (Lang et al. 1998).  In this study, cell volume (MCVM) was 
measured using an automatic cell analyzer, which completes its 
analysis within seconds.  Therefore, it can be expected that any 
compensatory volume regulatory changes would be incomplete 
and measured cell volume would still reflect initial fluid shifts 
cause by tonic insult to the cells. 
 There are several limitations to the present study.  First, the 
determinants of dMCV (hct, RBC, and MCVM) were measured in 
plasma, whereas osmolality, electrolyte, BUN, and glucose 
measurements were made in serum, which may have affected 
associations between dMCV and the various methods of estimating 
tonicity.  Ideally, all measurements would have been made in 
plasma because plasma is a better representation of the in vivo 
environment; however, serum is the preferred sample type for 
measurement of electrolytes and plasma samples were not 
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available at the time of sample retrieval for most dogs (Stockham 
and Scott 2008b).  Another concern is that prolonged storage of 
frozen samples could introduce artifact in the measurement of 
serum osmolality.  To the authors’ knowledge, stability of frozen 
canine serum for osmometric analysis has not been reported.  
However, a prospective study that examined dMCV and serum 
osmolality using fresh samples analyzed concurrently showed 
results similar to those reported here; therefore, the present results 
are likely valid (Reinhart, unpublished).  In this study, all blood 
samples were collected during SA-ICU hospitalization, but timing 
of collection was not standardized.  It is likely that some patients 
received treatment prior to sample collection; the number and 
degree of interventions performed prior to collection also likely 
varied among patients.  This limitation does not weaken the ability 
of dMCV to predict hypertonicity, but the summary data presented 
for dMCV, osmolality, and various clinicopathologic values should 
not be considered representative of a general SA-ICU population at 
admission.  Ideally, all blood collection would have been 
performed at presentation prior to treatment; however, this was 
precluded by retrospective nature of the study.  Similarly, the dogs 
in this study are a heterogeneous population of various breeds, 
ages, and disease processes.  Future studies could include 
assessment of tonicity in specific disease states such as diabetes 
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mellitus; in general survey populations stratified by breed, sex, or 
age; in hospitalized populations stratified by disease category or 
severity; or in longitudinal studies tracking changes in tonicity 
over time, with disease progression, or during treatment. 
 In conclusion, the results of this study support the use of 
dMCV (≥ 3 fl) a physiologic marker for overt serum hypertonicity 
(OsMM ≥ 320 mOsM) in dogs.  dMCV predicts hypertonicity 
estimated by measured osmolality better than by either calculated 
method, suggesting the influence of unmeasured effective osmoles 
in serum on dMCV. 
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Figure Captions 
Figure 1 – ROC Curves for dMCV predicting hypertonicity (OsM 
≥ 320 mOsM) as estimated by OsMM (A), OsMC(B), and OsMCE 
(C) 
Figure 2 – ROC curve for dMCV predicting mild hypertonicity 
(OsMM ≥ 300 mOsM)  
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Tables 
Table 1 – Summary statistics of pertinent clinicopathologic values, 
measured osmolality, and calculated values. 





Na 149 118 – 164 147 – 154 mmol/l 
K 4.5 3.1 – 6.6 2.6 – 5.3 mmol/l 
BUN 15 4 – 212 9 – 33 mg/dl 
Glucose 109 30 – 1108 73 – 113 mg/dl 
RBC 7.15 5.52 – 9.40 5.5 – 8.5 M/μl 
hct 48 35 – 66 35 – 55 % 
MCVM 69 62 – 76 60 – 77 fl 
OsMM 307.0 279.0 – 510.5
^
 n/a mOsM 
OsMC 319.4 296.0 – 377.1 n/a mOsM 
OsMCE 314.4 291.1 – 344.2 n/a mOsM 
dMCV 2.37 -2.94 – 6.92 n/a fl 
*These are the reference ranges reported by the Kansas State 
Veterinary Diagnostic Lab, Clinical Pathology Laboratory. 
^This value is unlikely to be the true osmolality of the sample, as a 
serum osmolality of 510 mOsM is incompatible with life, and 
likely represents technical error.  However, this value was 
repeatable using the freezing-point depression osmometer so was 
included in the data set.  Exclusion of this data point does not 
significantly alter the results of this study. 
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Table 2 – Comparison of dMCV for normosmolar and 
hyperosmolar dogs as determined by three osmolality methods. 
 Normosmolar Hyperosmolar 
P-
value 
 Median Range N Median Range N  
OsMM 2.13 fl 
-2.95 – 
6.87 




OsMC 1.79 fl 
-2.95 – 
6.25 




OsMCE 2.20 fl 
-2.95 – 
6.92 















OsMM 2.96 76 71 0.7738 
OsMC 2.47 67 68 0.7063 
OsMCE 2.96 73 71 0.7337 
 
